Title |
Therapeutic treatment with a novel hypoxia-inducible factor hydroxylase inhibitor (TRC160334) ameliorates murine colitis
|
---|---|
Published in |
Clinical and Experimental Gastroenterology, January 2014
|
DOI | 10.2147/ceg.s51923 |
Pubmed ID | |
Authors |
Ram Gupta, Anita R Chaudhary, Binita N Shah, Avinash V Jadhav, Shitalkumar P Zambad, Ramesh Chandra Gupta, Shailesh Deshpande, Vijay Chauthaiwale, Chaitanya Dutt |
Abstract |
Mucosal healing in inflammatory bowel disease (IBD) can be achieved by improvement of intestinal barrier protection. Activation of hypoxia-inducible factor (HIF) has been identified as a critical factor for barrier protection during mucosal insult and is linked with improvement in symptoms of colitis. Although prophylactic efficacy of HIF hydroxylase inhibitors in murine colitis have been established, its therapeutic efficacy in clinically relevant therapeutic settings have not been established. In the present study we aim to establish therapeutic efficacy of TRC160334, a novel HIF hydroxylase inhibitor, in animal models of colitis. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 20 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 5 | 25% |
Student > Ph. D. Student | 5 | 25% |
Student > Postgraduate | 3 | 15% |
Other | 2 | 10% |
Researcher | 2 | 10% |
Other | 1 | 5% |
Unknown | 2 | 10% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 5 | 25% |
Medicine and Dentistry | 5 | 25% |
Pharmacology, Toxicology and Pharmaceutical Science | 4 | 20% |
Agricultural and Biological Sciences | 2 | 10% |
Unknown | 4 | 20% |